111 related articles for article (PubMed ID: 33681675)
1. Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure.
Spradling PR; Zhong Y; Moorman AC; Rupp LB; Lu M; Gordon SC; Teshale EH; Schmidt MA; Daida YG; Boscarino JA;
Hepatol Commun; 2021 Mar; 5(3):400-411. PubMed ID: 33681675
[TBL] [Abstract][Full Text] [Related]
2. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.
Spradling PR; Xing J; Rupp LB; Moorman AC; Gordon SC; Lu M; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Holmberg SD;
J Clin Gastroenterol; 2018 Aug; 52(7):641-647. PubMed ID: 28590325
[TBL] [Abstract][Full Text] [Related]
3. Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus.
Kanwal F; Kramer JR; El-Serag HB; Frayne S; Clark J; Cao Y; Taylor T; Smith D; White D; Asch SM
Clin Infect Dis; 2016 Aug; 63(3):291-9. PubMed ID: 27131869
[TBL] [Abstract][Full Text] [Related]
4. Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.
Marcus JL; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Lam JO; Pauly MP; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ
Public Health Rep; 2018; 133(4):452-460. PubMed ID: 29750893
[TBL] [Abstract][Full Text] [Related]
5. Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016.
Jung J; Du P; Feldman R; Kong L; Riley T
J Manag Care Spec Pharm; 2019 Nov; 25(11):1236-1242. PubMed ID: 31663464
[TBL] [Abstract][Full Text] [Related]
6. Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020.
Thompson WW; Symum H; Sandul A; ; Gupta N; Patel P; Nelson N; Mermin J; Wester C
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(32):1011-1017. PubMed ID: 35951484
[TBL] [Abstract][Full Text] [Related]
7. Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans.
Beck KR; Kim NJ; Khalili M
Ann Hepatol; 2018; 17(3):413-418. PubMed ID: 29735789
[TBL] [Abstract][Full Text] [Related]
8. Short article: Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: a retrospective study in a large urban tertiary center.
Sims OT; Guo Y; Shoreibah MG; Venkata K; Fitzmorris P; Kommineni V; Romano J; Massoud OI
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1219-1222. PubMed ID: 28857899
[TBL] [Abstract][Full Text] [Related]
9. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
[TBL] [Abstract][Full Text] [Related]
10. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
[TBL] [Abstract][Full Text] [Related]
11. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.
Corcorran MA; Tsui JI; Scott JD; Dombrowski JC; Glick SN
Drug Alcohol Depend; 2021 Mar; 220():108525. PubMed ID: 33461152
[TBL] [Abstract][Full Text] [Related]
12. Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.
Yaya I; Roux P; Marcellin F; Wittkop L; Esterle L; Spire B; Dominguez S; Elegbe BA; Piroth L; Sogni P; Salmon-Ceron D; Carrieri MP;
PLoS One; 2018; 13(7):e0199874. PubMed ID: 29975764
[TBL] [Abstract][Full Text] [Related]
13. Association of the Extension for Community Healthcare Outcomes Project With Use of Direct-Acting Antiviral Treatment Among US Adults With Hepatitis C.
Tran L; Feldman R; Riley T; Jung J
JAMA Netw Open; 2021 Jul; 4(7):e2115523. PubMed ID: 34213557
[TBL] [Abstract][Full Text] [Related]
14. Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?
Jain MK; Thamer M; Therapondos G; Shiffman ML; Kshirsagar O; Clark C; Wong RJ
Hepatology; 2019 Jan; 69(1):51-63. PubMed ID: 30019478
[TBL] [Abstract][Full Text] [Related]
15. High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study.
Yee J; Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Doyle JS; Davies J; Martinello M; Marks P; Dore GJ; Matthews GV;
Hepatol Commun; 2022 Mar; 6(3):496-512. PubMed ID: 34729957
[TBL] [Abstract][Full Text] [Related]
16. Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017.
Spradling PR; Xing J; Rupp LB; Moorman AC; Gordon SC; Lu M; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Holmberg SD;
J Clin Gastroenterol; 2021 Jan; 55(1):77-83. PubMed ID: 32250999
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
Lam JO; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ; Marcus JL
Int J STD AIDS; 2019 Jun; 30(7):689-695. PubMed ID: 31046611
[TBL] [Abstract][Full Text] [Related]
19. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
[No Abstract] [Full Text] [Related]
20. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
Su F; Green PK; Berry K; Ioannou GN
Hepatology; 2017 Feb; 65(2):426-438. PubMed ID: 27775854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]